Advertisement
Document › Details
Arix Bioscience plc. (5/31/17). "Press Release: Arix Bioscience to Present at Jefferies 2017 Global Healthcare Conference in New York". London.
Arix Bioscience plc (LSE: ARIX) (“Arix Bioscience” or “the Company”), a global healthcare and life science company supporting medical innovation, today announces that Joe Anderson, Chief Executive Officer of Arix Bioscience, will present at the Jefferies 2017 Global Healthcare Conference to be held on 6-8 June in New York, US.
The presentation will be on Thursday, 8 June at 4pm EDT and a webcast of the presentation will be available for 90 days on the conference website.
Additionally, a number of Arix’s Group Businesses will be present at the conference, including:
Jan-Anders Karlsson, Chief Executive Officer of Verona Pharma plc, will present on Thursday, 8 June at 11.30am EDT. Verona Pharma is a listed clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases with significant unmet needs.
The management team at Autolus Ltd will attend the conference and will be available for 1-1 meetings. Autolus is a private biopharmaceutical company focused on the development and commercialisation of engineered T-cell immunotherapy products based on its proprietary T-cell programming technology.
For more information, please contact:
Arix Bioscience plc
Joe Anderson, CEO
+44 (0) 20 7290 1052
Consilium Strategic Communications
Mary-Jane Elliott, Jessica Hodgson, Ivar Milligan
+44 (0)20 3709 5700
arix@consilium-comms.com
About Arix Bioscience plc
Arix Bioscience plc is a global healthcare and life science company supporting medical innovation. Headquartered in London and with an office in New York, Arix Bioscience sources, finances and builds world class healthcare and life science businesses addressing medical innovation at all stages of development. Operations are supported by privileged access to breakthrough academic science and strategic relationships with leading research accelerators and global pharmaceutical companies.
Arix Bioscience plc is listed on the Main Market of the London Stock Exchange.
For further information, please visit www.arixbioscience.com
Record changed: 2023-06-05 |
Advertisement
More documents for Arix Bioscience (Group)
- [1] Evommune, Inc.. (4/26/23). "Press Release: Evommune Closes $50 Million Series B Financing to Advance Broad Pipeline of Therapies to Treat Chronic Inflammatory Diseases". Palo Alto, CA....
- [2] UCB S.A.. (3/9/23). "Press Release: UCB’s Board of Directors Appoints Jonathan Peacock as New Chair". Brussels....
- [3] Sorriso Pharmaceuticals, Inc.. (12/22/21). "Press Release: Sorriso Pharmaceuticals Launches with $31 Million to Develop Novel Class of Orally Delivered Cytokine Antibodies to Treat Inflammatory Conditions". Salt Lake City, UT....
- [4] Arix Bioscience plc. (12/22/21). "Press Release: Arix Bioscience Co-leads $31 Million Series A Financing for New Portfolio Company Sorriso Pharmaceuticals". London....
- [5] Rentschler Biopharma SE. (9/20/21). "Press Release: Rentschler Biopharma Appoints Dr. Christian Schetter as Chief Scientific Officer, Strengthening Scientific Focus". Laupheim & Milford, MA....
- [6] Pyxis Oncology, Inc.. (3/30/21). "Press Release: Pyxis Oncology Closes $152 Million Series B Financing to Further Advance Portfolio of Biologics". Cambridge, MA....
- [7] Arix Bioscience plc. (3/24/21). "Press Release: Strategy Implementation Review". London....
- [8] Arix Bioscience plc. (11/5/20). "Press Release: VelosBio to Be Acquired by Merck for $2.75 Billion". London....
- [9] GenSight Biologics S.A.. (10/22/20). "Press Release: GenSight Biologics Successfully Raises €25 Million in an Oversubscribed Private Placement With US and European Institutional Investors". Paris....
- [10] VelosBio Inc.. (7/8/20). "Press Release: VelosBio Raises $137 Million in Series B Financing to Advance Development of ROR1-Directed Therapeutics in Oncology"....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top